Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4

Background & Aims Egypt has the highest prevalence of chronic hepatitis C virus (HCV) infection in the world, and more than 90% of patients are infected with genotype 4 virus. We evaluated the efficacy and safety of the HCV polymerase inhibitor sofosbuvir in combination with ribavirin in HCV gen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2015-09, Vol.63 (3), p.581-585
Main Authors: Doss, Wahid, Shiha, Gamal, Hassany, Mohamed, Soliman, Reham, Fouad, Rabab, Khairy, Marwa, Samir, Waleed, Hammad, Radi, Kersey, Kathryn, Jiang, Deyuan, Doehle, Brian, Knox, Steven J, Massetto, Benedetta, McHutchison, John G, Esmat, Gamal
Format: Article
Language:English
Subjects:
Adult
Aged
Antiviral agents
Antiviral Agents - administration & dosage
Drug Therapy, Combination
Egypt
Female
Gastroenterology and Hepatology
Genotype
Genotype 4
Hepacivirus - genetics
Hepatitis C
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Humans
Male
Middle Aged
Polymerase inhibitor
Ribavirin - administration & dosage
Ribavirin - adverse effects
Sofosbuvir
Sofosbuvir - administration & dosage
Sofosbuvir - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims Egypt has the highest prevalence of chronic hepatitis C virus (HCV) infection in the world, and more than 90% of patients are infected with genotype 4 virus. We evaluated the efficacy and safety of the HCV polymerase inhibitor sofosbuvir in combination with ribavirin in HCV genotype 4 patients in Egypt. Methods Treatment-naïve or treatment-experienced patients with genotype 4 HCV infection (n = 103) were randomly assigned to receive either 12 or 24 weeks of sofosbuvir 400 mg and ribavirin 1000–1200 mg daily. Randomization was stratified by prior treatment experience and by presence or absence of cirrhosis. The primary endpoint was the percentage of patients with HCV RNA
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2015.04.023